#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adult T-cell lymphoma/leukaemia refractory Pelizaeus-Merzbacher disease Epidermolysis bullosa Juvenile psoriatic arthritis Synovial sarcoma metastatic Paget's disease of the vulva Chronic cutaneous lupus erythematosus Ovarian cancer Retinal artery occlusion Soft tissue necrosis Spinal cord injury cervical Mantle cell lymphoma Congenital disorder of glycosylation Chronic myelomonocytic leukaemia Thermal burn More trials…

    Learn about Rare Diseases

    Arterial tortuosity syndrome – Basic Information Myelodysplastic syndrome – Basic Information Idiopathic inflammatory myopathy – Basic Information Osteosarcoma – Basic Information Ehlers-Danlos syndrome – Basic Information Pleural mesothelioma malignant – Diagnostics Rett syndrome – Trials in Disease Atypical haemolytic uraemic syndrome – Life with Disease Erdheim-Chester disease – Diagnostics Primary biliary cholangitis – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Remifentanil Iti-1284 Salmeterol Xinafoate Rupatadine Encaleret Sulfate YL201 Db-Oto-5 Rezvilutamide Cilgavimab LY3372993 Posdinemab Deferiprone Emapalumab GSKVX000000070248 Lacnotuzumab Alternaria Alternata Extract Lysine Aspirin Ly3556050 Fludarabine Phosphate Ph. Eur. DAPIGLUTIDE More therapies…

    Learn about Your Condition

    Drug dependence Cervix carcinoma stage IV Injury Chronic myeloid leukaemia Testicular leiomyosarcoma Cold urticaria Onychomycosis Hepatorenal syndrome Haemorrhoids Polymyalgia rheumatica Colorectal cancer Double hit lymphoma Dementia Alzheimer's type Tendon disorder Pruritus More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Bladder cancer

  • Study on Pre-Operative Nivolumab and Relatlimab for Adults with Stage II-IIIa Muscle-Invasive Bladder Cancer

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Bladder cancer stage II
    • Bladder cancer stage III
    • Bladder cancer
    Investigated Drugs:
    • Nivolumab
    • Relatlimab
    The Netherlands

  • Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Finland France Germany Greece +7

  • Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Cisplatin
    • Fluorouracil
    • Gemcitabine Hydrochloride
    Czechia Estonia France Hungary Italy Latvia +5

  • Study of Pembrolizumab, Vibostolimab, and Favezelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Unresponsive to BCG Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Vibostolimab
    • Favezelimab
    • Pembrolizumab
    Finland France Greece Italy The Netherlands Spain +1

  • Study on the Effectiveness of Ipilimumab and Nivolumab for Patients with Bladder Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Ipilimumab
    • Nivolumab
    The Netherlands

  • Study of Sacituzumab Govitecan for Patients with Muscle-Invasive Bladder Cancer Unable or Unwilling to Use Cisplatin-Based Chemotherapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    Italy
Previous Page
1 … 6 7 8 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!